Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) released its quarterly earnings results on Thursday. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.04, MarketWatch Earnings reports. SNSE stock traded down $0.19 on Friday, reaching $2.84. 992 shares of the company were exchanged, compared to its average volume of […]
/PRNewswire/ Cambrian Biopharma, a multi-asset longevity biotech, today announced a licensing agreement with Novartis to advance novel, selective compounds.
/PRNewswire/ Cambrian Biopharma, a multi-asset longevity biotech, today announced a licensing agreement with Novartis to advance novel, selective compounds.